Bayer's performance in the stock market has been dotted with numerous events and outcomes in the recent past. The company’s shares have been subject to significant price fluctuations, with dips being majorly influenced by legal battles and restructuring drawbacks. Recently, Bayer shares plummeted close to
6% after an order to pay $2.25 billion in damages. The company has generally been experiencing a slump in share prices, with the stock reaching an
18-year low following the termination of the asundexian trial. The trials related to Monsanto, with subsequent rulings playing substantial roles in shaping Bayer’s stock performance. Despite these setbacks, there were moments of recovery where shares surged after
Monsanto's successful appeal win. Bayer’s financial performance too was under par, with the company’s Q1 adjusted profit declining less than expected. The company recently took a decision to cut dividends in an attempt to manage indebtedness, a move that slightly affected the stock's performance. Other significant events impacting Bayer’s market performance include the
halt of a blood-thinning drug trial, which led to a notable stock plunge and internal restructuring aimed at saving costs.
BAYER Stocks News Analytics from Tue, 25 Jul 2023 07:00:00 GMT to Fri, 24 May 2024 03:01:01 GMT -
Rating -4
- Innovation -5
- Information 7
- Rumor -8